In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Regeneron Pharmaceuticals REGN with a Buy rating and $350.00 price target.
In the report, Canaccord Genuity noted, “We are initiating coverage of Regeneron with a BUY rating and $350 price target. Regeneron has the top pipeline in biotech, in our view, with two Phase 3 validated drugs in development, and an additional Phase 2 validated asset. We expect continued pipeline success to drive long-term growth going forward.”
Regeneron Pharmaceuticals closed on Tuesday at $288.08.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in